- Record: found
- Abstract: not found
- Article: not found
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo
1 ,
Brian A. Jonas
1 ,
Vinod Pullarkat
1 ,
Michael J. Thirman
1 ,
Jacqueline S. Garcia
1 ,
Andrew H. Wei
1 ,
Marina Konopleva
1 ,
Hartmut Döhner
1 ,
Anthony Letai
1 ,
Pierre Fenaux
1 ,
Elizabeth Koller
1 ,
Violaine Havelange
1 ,
Brian Leber
1 ,
Jordi Esteve
1 ,
Jianxiang Wang
1 ,
Vlatko Pejsa
1 ,
Roman Hájek
1 ,
Kimmo Porkka
1 ,
Árpád Illés
1 ,
David Lavie
1 ,
Roberto M. Lemoli
1 ,
Kazuhito Yamamoto
1 ,
Sung-Soo Yoon
1 ,
Jun-Ho Jang
1 ,
Su-Peng Yeh
1 ,
Mehmet Turgut
1 ,
Wan-Jen Hong
1 ,
Ying Zhou
1 ,
Jalaja Potluri
1 ,
Keith W. Pratz
1
August 13 2020
August 13 2020
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d6279034e287">Older patients with acute myeloid leukemia (AML)
have a dismal prognosis, even after
treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising
efficacy in a previous phase 1b study.
</p>